Dr. Lindi H. Vanderwalde, MD

Dr. Vanderwalde practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Vanderwalde's NPI, 1578788402, was assigned on April 16, 2007. Dr. Vanderwalde graduated from Perelman School of Medicine - Philadelphia in 2004. Dr. Vanderwalde's Tennessee license number on file is 50312.

Dr. Vanderwalde's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Vanderwalde's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Vanderwalde to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vanderwalde practices, 2 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Vanderwalde's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Vanderwalde is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Vanderwalde's licenses on file in 3 states: Tennessee, California and Mississippi.

Dmand AI lists breast reconstruction, breast surgery, mastectomy and removal of damaged skin or skin graft among the conditions Dr. Vanderwalde treats.

CMS data shows 64 Medicare services from Dr. Vanderwalde across 2 procedure codes in 2024, for 52 Medicare patients. Medicare paid $1,370 for them. Every service was in an office.

CMS counts 52 Medicare patients who saw Dr. Vanderwalde in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Vanderwalde's median patient age at 56, with 100% women.

In 2024, Dr. Vanderwalde wrote 51 Medicare Part D claims for 22 patients. 98% of them were for generic drugs. CMS names the drug for 35 of them, across 2 drugs with 11 or more claims each, at $553 in total drug cost. In 2023, CMS named 79 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Vanderwalde for performance year 2024, reported as part of a group. Dr. Vanderwalde accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Vanderwalde, published from 2018 to 2024. Dr. Vanderwalde's most frequent co-authors are Thomas Lynn Eisenhauer, MD, Tina J. Hieken, MD and Alyssa D. Throckmorton, MD.

CMS Open Payments shows 19 general payments to Dr. Vanderwalde from 10 drug and device companies from 2016 to 2019. Food and beverage make up the largest share, 100% of the total. Genentech, Inc. paid the most, $144.

Dmand AI lists 2 awards for Dr. Vanderwalde, most recently ACS Fellow in 2012.

Dr. Vanderwalde graduated from Perelman School of Medicine - Philadelphia in 2004. Dr. Vanderwalde is a member of ACS.

Dr. Vanderwalde is in network with 11 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.